0 CHECKOUT

Intermittent Claudication - Pipeline Review, H2 2015

  • ID: 3422675
  • August 2015
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cytokinetics, Inc.
  • DNAVEC Corporation
  • Kowa Company, Ltd.
  • LTT Bio-Pharma Co., Ltd.
  • Nuo Therapeutics, Inc.
  • MORE

Intermittent Claudication - Pipeline Review, H2 2015

Summary

The report ‘Intermittent Claudication - Pipeline Review, H2 2015’, provides an overview of the Intermittent Claudication’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cytokinetics, Inc.
  • DNAVEC Corporation
  • Kowa Company, Ltd.
  • LTT Bio-Pharma Co., Ltd.
  • Nuo Therapeutics, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Intermittent Claudication Overview

Therapeutics Development

Pipeline Products for Intermittent Claudication - Overview

Pipeline Products for Intermittent Claudication - Comparative Analysis

Intermittent Claudication - Therapeutics under Development by Companies

Intermittent Claudication - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Intermittent Claudication - Products under Development by Companies

Intermittent Claudication - Companies Involved in Therapeutics Development

Cytokinetics, Inc.

DNAVEC Corporation

Kowa Company, Ltd.

LTT Bio-Pharma Co., Ltd.

Nuo Therapeutics, Inc.

Pluristem Therapeutics Inc.

Intermittent Claudication - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ALD-301 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DVC1-0101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

K-134 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LT-0101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PLX-PAD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tirasemtiv - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Intermittent Claudication - Recent Pipeline Updates

Intermittent Claudication - Dormant Projects

Intermittent Claudication - Discontinued Products

Intermittent Claudication - Product Development Milestones

Featured News & Press Releases

Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study

Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study

Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany

Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells

Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research

Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Intermittent Claudication, H2 2015

Number of Products under Development for Intermittent Claudication - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Intermittent Claudication - Pipeline by Cytokinetics, Inc., H2 2015

Intermittent Claudication - Pipeline by DNAVEC Corporation, H2 2015

Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2015

Intermittent Claudication - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015

Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2015

Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Intermittent Claudication Therapeutics - Recent Pipeline Updates, H2 2015

Intermittent Claudication - Dormant Projects, H2 2015

Intermittent Claudication - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Intermittent Claudication, H2 2015

Number of Products under Development for Intermittent Claudication - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Cytokinetics, Inc.
DNAVEC Corporation
Kowa Company, Ltd.
LTT Bio-Pharma Co., Ltd.
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx